News
December 3, 2018
Toronto, December 3, 2018 – Brand-name drug companies’ research and development spending as a percentage of sales in Canada is less than half of the 10 percent the industry committed to when their periods of market exclusivity were first increased in 1987, according to the most recent annual report from the federal government’s Patented Medicine Prices Review Board (PMPRB).
November 22, 2018
Toronto – November 22, 2018 – Biosimilars Canada, the national association representing Canada’s biosimilar medicines industry, today announced that Innomar Strategies, Canada's leading specialty pharmaceuticals service provider has been selected as the preferred provider for the Biosimilars Canada Patient Support Program (PSP) platform. The platform will provide a common suite of PSP services for Biosimilars Canada members going forward that can be customized to meet the individual needs of the therapy, the biosimilar sponsor and payers.
October 2, 2018
Montréal, October 2, 2018 – The following is a statement by Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), on the election of François Legault and the Coalition Avenir Québec in Quebec on Monday :